DDInter1570 DDInter1140
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Ranolazine {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tetracycline
Tetracycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Ranolazine {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Ranolazine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Ranolazine {u} (Compound) causes {v} (Side Effect) Hearing impaired
Hearing impaired {u} (Side Effect) is caused by {v} (Compound) Perflutren
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Guaifenesin {u} (Compound) resembles {v} (Compound) Penbutolol
Penbutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Ranolazine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Ranolazine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Ranolazine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Ranolazine (Compound) causes Hearing impaired (Side Effect) and Hearing impaired (Side Effect) is caused by Perflutren (Compound) and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Ranolazine (Compound) resembles Guaifenesin (Compound) and Guaifenesin (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)